Norelle C. Wildburger, Ph.D.

Affiliations: 
 
Area:
Alzheimer's & Parkinson's disease, mass spectrometry, Top-down proteomics, biomarkers, protein-protein interactionsVoltage-gated sodium channels,
Website:
https://www.researchgate.net/profile/Norelle_Wildburger?ev=hdr_xprf&_sg=YfPqzrTgz3eM5pIzyYjRh4nTIO8Q2WamDgJW5wl4T3FSr6udWvBPzkoKbg3MpNM_j_eOPmH8qnJBj-C1lC8JHon3
Google:
"Norelle Wildburger"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Srzentić K, Fornelli L, Tsybin YO, et al. (2020) Interlaboratory Study for Characterizing Monoclonal Antibodies by Top-Down and Middle-Down Mass Spectrometry. Journal of the American Society For Mass Spectrometry
Paterson RW, Gabelle A, Lucey BP, et al. (2019) SILK studies - capturing the turnover of proteins linked to neurodegenerative diseases. Nature Reviews. Neurology
Bateman RJ, Mawuenyega KG, Wildburger NC. (2019) The structure of amyloid-β dimers in Alzheimer's disease brain: a step forward for oligomers. Brain : a Journal of Neurology. 142: 1168-1169
Scala F, Nenov MN, Crofton EJ, et al. (2018) Environmental Enrichment and Social Isolation Mediate Neuroplasticity of Medium Spiny Neurons through the GSK3 Pathway. Cell Reports. 23: 555-567
Wildburger NC, Gyngard F, Guillermier C, et al. (2018) Amyloid-β Plaques in Clinical Alzheimer's Disease Brain Incorporate Stable Isotope Tracerand Exhibit Nanoscale Heterogeneity. Frontiers in Neurology. 9: 169
Wildburger NC, Esparza TJ, LeDuc RD, et al. (2017) Diversity of Amyloid-beta Proteoforms in the Alzheimer's Disease Brain. Scientific Reports. 7: 9520
Brody DL, Jiang H, Wildburger N, et al. (2017) Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease. Alzheimer's Research & Therapy. 9: 62
Hsu WJ, Wildburger N, Haidacher SJ, et al. (2017) PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease. Experimental Neurology
Esparza TJ, Wildburger NC, Jiang H, et al. (2016) Soluble Amyloid-beta Aggregates from Human Alzheimer's Disease Brains. Scientific Reports. 6: 38187
Hsu WJ, Scala F, Nenov MN, et al. (2016) CK2 activity is required for the interaction of FGF14 with voltage-gated sodium channels and neuronal excitability. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology
See more...